← Back to Search

Unknown

SCD-044 for Plaque Psoriasis (SOLARES-PsO-1 Trial)

Phase 2
Recruiting
Research Sponsored by Sun Pharmaceutical Industries Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged at least 18 years.
Subjects with no history of active TB or symptoms of TB
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 56
Awards & highlights

SOLARES-PsO-1 Trial Summary

This trial is testing a new treatment for plaque psoriasis, comparing it to a placebo. The trial is double-blind, meaning neither the participants nor the researchers will know who is receiving the treatment or the placebo.

Who is the study for?
This trial is for adults over 18 with moderate to severe plaque psoriasis, a skin condition characterized by scaly patches. Participants must have had the condition for at least 6 months and should not be pregnant or breastfeeding. They shouldn't have tuberculosis (TB) or need other psoriasis treatments during the study.Check my eligibility
What is being tested?
The study tests SCD-044 in three different doses compared to a placebo to see its effect on plaque psoriasis. It's conducted across multiple centers where participants are randomly assigned to receive either the drug or placebo without knowing which one they're getting.See study design
What are the potential side effects?
While specific side effects of SCD-044 aren't listed, common ones for new psoriasis treatments may include skin irritation, headaches, fatigue, nausea, and potential risks associated with immune system changes.

SOLARES-PsO-1 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have never had active TB nor shown symptoms of it.

SOLARES-PsO-1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 56
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 56 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Psoriasis Area and Severity Index (PASI) score
Secondary outcome measures
Change in Psoriasis Area and Severity Index (PASI) scores
Change in body surface area (BSA)
Dermatology Life Quality Index (DLQI)
+7 more

SOLARES-PsO-1 Trial Design

4Treatment groups
Active Control
Placebo Group
Group I: SCD-044 Tablets_Dose 1Active Control1 Intervention
SCD-044 tablets at Dose 1
Group II: SCD-044 Tablets_Dose 2Active Control1 Intervention
SCD-044 tablets at Dose 2
Group III: SCD-044 Tablets_Dose 3Active Control1 Intervention
SCD-044 tablets at Dose 3
Group IV: Placebo of SCD-044 productPlacebo Group1 Intervention
Placebo of SCD-044 study drug

Find a Location

Who is running the clinical trial?

Sun Pharmaceutical Industries LimitedLead Sponsor
64 Previous Clinical Trials
13,271 Total Patients Enrolled

Media Library

Placebo (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04566666 — Phase 2
Plaque Psoriasis Research Study Groups: Placebo of SCD-044 product, SCD-044 Tablets_Dose 1, SCD-044 Tablets_Dose 2, SCD-044 Tablets_Dose 3
Plaque Psoriasis Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT04566666 — Phase 2
Placebo (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04566666 — Phase 2
Plaque Psoriasis Patient Testimony for trial: Trial Name: NCT04566666 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What have been the most serious adverse effects linked with SCD-044 Tablets_Dose 1?

"SCD-044 Tablets_Dose 1 is still being studied for efficacy in clinical trials, but there is some data supporting its safety--meaning it received a 2."

Answered by AI

How many locations are conducting this experiment?

"If you are considering enrolling in this study, please note that there are 18 sites located across Los Angeles, Fort Lauderdale and North Hollywood. Additionally, the other locations for this trial are situated throughout America. To reduce stress related to travel, we recommend enrolling at a site closest to your home."

Answered by AI

Is this research project actively looking for more participants?

"Yes, the information available on clinicaltrials.gov reveals that this study is presently looking for volunteers. This trial was first advertised on March 26th 2021 and updated last on August 26th 2022. In total, 240 patients are needed from 18 distinct sites."

Answered by AI

Who else is applying?

What state do they live in?
Indiana
What site did they apply to?
Site # 08
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1
3+

Why did patients apply to this trial?

I have tried several drugs that have not worked. I am taking one now that has helped, but is not working as well as it used too.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis
2021. "To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04566666.
All > Psoriasis > Plaque Psoriasis
~59 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top